�Takeda Pharmaceutical Company Limited (TOKYO:4502) and Affymax, Inc. (Nasdaq:AFFY) today announced their agreement to suspend co-development of Hematide� to treat chemotherapy-induced anemia and to focus all development efforts for Hematide� on the treatment of chronic kidney disease related anemia. Takeda and Affymax continue to be encouraged by the potential of bringing Hematide, a commodious, once monthly treatment alternative, to the millions of chronic kidney disease patients suffering from anemia and believe this represents a significant opportunity for the two companies.
Takeda has been conducting Phase I clinical studies of Hematide� for the treatment of chemotherapy-induced anemia in the U.S. and Japan. However, the companies have decided to suspend development of Hematide in oncology and not to enroll newfangled patients in the on-going Phase I clinical trial of the product in chemotherapy-induced anaemia given the uncertain regulative landscapes for
